Optimal Strategy for Colorectal Cancer Patients’ Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9

<div>Images of CTCs and CTECs in CRC by subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) under fluorescence microscope (×400). (a) DAPI+/CD45−/CEP8 = 3 (white arrow: triploid CTC); (b) DAPI+/CD45−/CEP8 &gt; 5 (white arrow: multiploidy CTC); (c) DAPI+/CD45+/CEP8 = 2 (red arrow: WBC); (d) DAPI+/CD45−/CD31+/CEP8 &gt; 5 (green arrow: CTEC); (e) distribution of CTCs according to ploidy. DAPI: blue, CD45: red, CEP8: orange, CD31: green.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Optimal Strategy for Colorectal Cancer Patients’ Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9 

Figure 1 | Optimal Strategy for Colorectal Cancer Patients’ Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9 